<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Parry, Nicola</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Asnis, Gregory M.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Higher Doses of Levomilnacipran May Benefit Patients with Severe Depression</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-06-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">20-20</style></pages><abstract><style  face="normal" font="default" size="100%">This article presents a poster with results of a Phase 3 trial to evaluate the efficacy and tolerability of levomilnacipran extended-release (ER) dose in adult patients with major depressive disorder [APA 2014 (poster NR6-087); NCT00969709]. The results of the study indicated that higher doses of levomilnacipran ER may benefit some patients, including those with moderate to severe depression.</style></abstract><number><style face="normal" font="default" size="100%">8</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>